Madrigal Believes It Holds The Key To NASH: Clearing The Fat
Emerging Company Profile: With its first-in-class selective THR beta agonist, Madrigal thinks it may have a candidate, now in Phase II, that will offer reversal of liver damage in NASH patients with an excellent safety profile. It hopes to begin Phase III studies with MGL-3196 before the end of 2018.
You may also be interested in...
Analysts and investors also voice excitement about the THR-beta agonist's lipid-lowering effects to date. For Madrigal, the key will be replicating its 12-week data at 36 weeks, when the trial ends.
As Gilead’s ASK1 inhibitor nears Phase III, Intercept may be plagued by slower-than-expected enrollment of its Phase III trial for Ocaliva. A recent Biomedtracker survey finds liver docs may be more positively inclined toward the Gilead candidate.
Biotech gets $50m up front, up to $650m in milestones, significant royalties and the option to co-promote emricasan in NASH in the US. Novartis also may combine the caspase inhibitor with its Phase II FXR agonist.